Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse

BACKGROUND: Adaptive CD19-targeted chimeric antigen receptor (CAR) T-cell transfer has become a promising treatment for leukemia. Although patient responses vary across different clinical trials, reliable methods to dissect and predict patient responses to novel therapies are currently lacking. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lunan, Ma, Chao, Zhang, Zhuoyu, Witkowski, Matthew T, Aifantis, Iannis, Ghassemi, Saba, Chen, Weiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730379/
https://www.ncbi.nlm.nih.gov/pubmed/36600553
http://dx.doi.org/10.1136/jitc-2022-005360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730379/
https://www.ncbi.nlm.nih.gov/pubmed/36600553
http://dx.doi.org/10.1136/jitc-2022-005360

Ejemplares similares